Laura Ardighieri

ORCID: 0000-0002-6200-9671 · 6 papers in corpus
2022
Journal of personalized medicine ·doi:10.3390/jpm12111852

Uterine leiomyomas usually arise from the uterine body (95%), and rarely from the cervix (0.6%) or other urogenital sites. Lipoleiomyomas are benign, uncommon variants of leiomyomas (0.03-0.2%), histologically composed of smooth muscle cell…

review 2021
Journal of Obstetrics and Gynaecology Research ·doi:10.1111/jog.14635

AIM: The scar of cesarean section (CS) is the most common site of abdominal wall endometriosis (AWE), whose tumor degeneration has been reported in an increasing number of cases; the most frequent histological type is clear cell carcinoma (…

2020
Journal of clinical medicine ·doi:10.3390/jcm9082552

BackgroundIntestinal metaplasia/differentiation in primary endometrial carcinomas is an uncommon phenomenon, with only few cases described.Material and methodsWe performed a systematic review of endometrial carcinomas with intestinal metapl…

2017
Journal of experimental & clinical cancer research : CR ·doi:10.1186/s13046-017-0536-y

BackgroundEpithelial ovarian cancer (EOC) is a spectrum of different diseases, which makes their treatment a challenge. Forkhead box M1 (FOXM1) is an oncogene aberrantly expressed in many solid cancers including serous EOC, but its role in …

2014
The Journal of Pathology ·doi:10.1002/path.4293

There is debate as to whether peritoneal implants associated with serous borderline tumours/atypical proliferative serous tumours (SBT/APSTs) of the ovary are derived from the primary ovarian tumour or arise independently in the peritoneum.…

2013
The American journal of surgical pathology ·doi:10.1097/pas.0b013e3182889dc3

ARID1A is a recently identified tumor suppressor that functions in chromatin remodeling. Inactivating mutations of ARID1A and loss of its expression most frequently occur in ovarian clear cell carcinoma, ovarian endometrioid carcinoma, and …